[{"id":"99d11d88-e385-44ef-8e80-b24d60ceafac","acronym":"SOLAR","url":"https://clinicaltrials.gov/study/NCT02322593","created_at":"2021-01-18T11:00:52.882Z","updated_at":"2024-07-02T16:36:19.328Z","phase":"Phase 3","brief_title":"Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer","source_id_and_acronym":"NCT02322593 - SOLAR","lead_sponsor":"Taiho Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • gimeracil +oteracil +tegafur +folinic acid (TAS-118)"],"overall_status":"Completed","enrollment":" Enrollment 711","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2021-12-20"}]